Neuland Laboratories Limited has informed the Exchange about General Updates

Regulatory & Legal View source PDF Explain this filing

NEULANDLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+3.3%Reaction day

₹11941.00

prior close

₹12052.00

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+1.1%+2.1% vs market

Pharmaceuticals peers, median of 147sector+0.8%+2.5% vs sector

On the reaction day the stock moved 2.1 pts more than Nifty Smallcap 250 and 2.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.3

10m

-0.4

15m

-0.2

30m

-0.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+3.3+1.1+2.1+0.8+2.5

Next day

+0.9-1.1+2.1-1.3+2.3

+1.2+0.1+1.2-0.9+2.1

+3.8-1.1+5.0-2.3+6.2

+3.5-1.8+5.3-2.4+5.9

+5.1+2.1+3.0+0.7+4.4

+4.9+4.5+0.5+3.1+1.9

15d

-5.0+8.2-13.3+4.4-9.4

-1.0+11.8-12.9+4.4-5.4

-1.3+15.4-16.8+7.0-8.4

+7.3+10.6-3.3+3.4+3.9

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 147Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The US FDA inspected Neuland Laboratories' Unit 2 manufacturing facility in Pashamylaram, Sangareddy District, from April 28 to May 2, 2025. At the end of the inspection, the FDA issued a Form 483 with a single observation related to building and facility management. The company has stated it will respond to the observation within the stipulated timelines set by the FDA. No data integrity or critical process-related observations were mentioned in the filing.

Likely market impact

A single minor observation on Form 483 is generally considered routine and not a major red flag for pharmaceutical companies. Shareholders should note that the company's response and any subsequent classification (like an EIR or warning letter) will be the next key updates to watch.